Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
TG THERAPEUTICS, INC.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-84.8% vs price
Base Case (Median)
-68.9% vs price
Bull Case (75th pct.)
13.9% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $61.53 | 13.9% | Medium (25%) |
| Growth Trajectory DCF | $201.15 | 272.5% | Medium (20%) |
| Graham Number | $16.79 | -68.9% | Medium (40%) |
| EV/EBITDA | $8.23 | -84.8% | Medium (20%) |
| EV/FCF | $1.22 | -97.7% | Medium (20%) |
Based on 5 out of 7 methods, TGTX appears fairly valued at the current price of $54.00. The base case fair value of $16.79 implies 68.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.